Turn the Tide Act
- Sponsor
- Sen. Shaheen, Jeanne [D-NH]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Jun 24, 2026
Bottom line
The Turn the Tide Act provides over $10 billion annually in direct federal appropriations and implements substantial policy changes to expand access to SUD treatment, prevention, and recovery services, while also addressing insurance coverage and workforce development.
What it actually does
This bill reauthorizes and appropriates significant funds for numerous federal programs aimed at combating the opioid and substance use disorder (SUD) crisis, primarily under the SUPPORT for Patients and Communities Act. It mandates changes to Medicaid and private health insurance to eliminate barriers to medication-assisted treatment (MAT) and opioid overdose reversal agents. Additionally, it establishes new grant programs and modifies existing ones to target resources to states most affected by the crisis and to support related public health and law enforcement initiatives.
Proponents argue
Proponents argue that this bill is a critical and comprehensive response to the ongoing opioid and SUD crisis, providing essential, sustained funding for programs that save lives and support communities. They emphasize that the direct appropriations ensure these vital programs can continue without interruption, while the insurance mandates remove financial and administrative barriers to life-saving treatments and overdose reversal medications. Supporters also highlight the bill's focus on workforce development, support for first responders, and targeted aid to the hardest-hit states as crucial elements for an effective national strategy.
Opponents contend
Opponents, particularly those focused on fiscal conservatism, may raise concerns about the scale of direct spending, arguing that appropriating funds 'out of any monies in the Treasury not otherwise appropriated' bypasses regular budgetary scrutiny and contributes to the national debt. Some may also express reservations about the federal mandates imposed on state Medicaid programs and private insurers, viewing them as an overreach into state and private sector autonomy, potentially leading to increased costs for these entities. Concerns could also be raised regarding the specific allocation formulas or the potential for funds to be less effectively utilized if the scope is broadened beyond opioid-specific interventions.
The bill is moderately long and dense due to numerous statutory amendments and explicit appropriations for many programs, requiring careful reading to grasp all changes and their implications.
Section 2(a)
Grants to Enhance Access to Substance Use Disorder Treatment
This provision reauthorizes and appropriates $4,000,000 annually for fiscal years 2027 through 2030 for grants aimed at enhancing access to substance use disorder treatment. These grants are provided under Section 3203(b) of the SUPPORT for Patients and Communities Act, ensuring continued funding for programs that expand treatment capacity.
Supporters argue
Proponents argue that sustained funding for treatment access grants is essential to meet the ongoing demand for substance use disorder care and to support the infrastructure necessary for effective recovery.
Critics contend
No specific opposition is typically raised against this provision, as funding for SUD treatment is broadly supported. Potential concerns might relate to the efficiency or targeting of the grants.
Tradeoffs
The tradeoff involves balancing the need for broad access to treatment with ensuring the most effective and evidence-based programs receive funding.
Section 3(q)
Preventing Overdoses of Controlled Substances
This section reauthorizes and appropriates a substantial amount of $516,000,000 annually for fiscal years 2027 through 2030 for programs under Section 392A(e) of the Public Health Service Act. These programs are dedicated to preventing overdoses of controlled substances, which includes a wide range of public health interventions and initiatives.
Section 4(a)
Reauthorization and Improvement of Recovery Housing Program
This provision reauthorizes the Recovery Housing Program, appropriating $60,000,000 annually for fiscal years 2027 through 2032. It significantly revises the funding formula to prioritize states with the greatest need, based on high unemployment rates (15% weight), low labor force participation rates (15% weight), and highest age-adjusted rates of drug overdose deaths (70% weight). It also extends the deadline for states to spend these funds, requiring at least 50% to be spent within 2 years.
Section 5(a)(1) and (3)
State Opioid Response Grants and Substance Abuse Prevention and Treatment Block Grants
This section appropriates $5,500,000,000 annually for fiscal years 2027 through 2031 for State Opioid Response (SOR) Grants, and $3,000,000,000 annually for fiscal years 2027 through 2031 (and $2,500,000,000 for FY32-36) for Substance Abuse Prevention and Treatment (SAPT) Block Grants. These are the largest funding streams in the bill, providing states with significant resources for SUD prevention and treatment.
Section 6(a)
Prohibition on Medicaid Utilization Controls for Medication-Assisted Treatment (MAT)
This section amends the Social Security Act to prohibit states from imposing any utilization control policies or procedures, including prior authorization requirements, on medication-assisted treatment (MAT) for substance use disorder, if they wish to receive federal Medicaid matching funds for such treatment. This change takes effect on October 1, 2026.
Section 7(a)
Mandated Coverage and No Cost-Sharing for Opioid Overdose Reversal Agents
This section mandates that group health plans and health insurance issuers (including those under ERISA and the Internal Revenue Code) must provide coverage for at least one formulation of an opioid overdose reversal agent and cannot impose any cost-sharing requirements or utilization controls (like prior authorization) for it. This applies to plan years beginning on or after January 1, 2027.
Section 9(a) and (b)
Medicaid Minimum Payment Rates and Increased FMAP for Behavioral Health Services
This section mandates that from October 1, 2026, to October 1, 2030, state Medicaid programs must pay physicians and 'applicable professionals' (e.g., clinical psychologists, social workers, MAT prescribers) for mental and behavioral health services related to SUD at a rate not less than 100% of Medicare Part B rates. To offset the increased cost to states, the federal medical assistance percentage (FMAP) for the additional expenditures due to this mandate will be 100%.
Section 10(h)
CMI Demonstration to Test Recovery Housing for Individuals With Opioid Use Disorder Under Medicaid
This section establishes a new demonstration project under the Center for Medicare and Medicaid Innovation (CMI) to test whether providing Medicaid managed care entities with elevated capitated budgets, coupled with flexibility to cover recovery housing, can reduce emergency department visits, hospitalizations, and overall Medicaid expenditures for eligible beneficiaries with opioid use disorder (OUD). The demonstration targets states with high overdose deaths and low physician reimbursement rates.
This provision amends the 21st Century Cures Act to allow State Opioid Response (SOR) grant funds to be used to support substance use disorder treatment and related services for individuals with *any* SUD diagnosis, not solely opioid use disorder. It also clarifies that states can allocate funds to local governments.
Section 5(a)(2)
Why it matters:This is likely standard legislative practice for amending existing statutes. The change broadens the scope of a major funding stream, which could be seen as a policy enhancement rather than something to hide.
Case for: Proponents argue that expanding the scope of SOR grants to cover all SUDs allows for a more holistic and integrated approach to addiction treatment, recognizing that many individuals have co-occurring disorders or primary SUDs other than opioids. This flexibility can improve patient care and program effectiveness.
Case against: Some might argue that broadening the scope could dilute the original intent and focus of the 'Opioid Response' grants, potentially diverting resources from the specific opioid crisis if not carefully managed. This could lead to less impact on the opioid epidemic itself.
Estimated impact: This change affects the use of $5.5 billion annually in SOR grants, allowing for a broader application of these funds across the spectrum of SUDs.
This provision outlines that 15 percent of the remaining State Opioid Response (SOR) grant funds (after the Tribal set-aside) shall be made available to states with the highest mortality rate related to opioid use disorders. Crucially, it directs the Secretary to develop a formula that 'avoids a significant cliff between States with similar mortality rates to prevent unusually large changes in certain States when compared to prior year allocations, including consideration of new formula methodologies to avoid such funding cliffs.'
Section 5(b)(2)
Why it matters:This is a standard technical detail for grant allocation formulas, aimed at ensuring fairness and stability in funding for states, which is a common concern in federal grant programs.
Case for: Proponents argue that this 'no cliff' provision is essential for states to maintain stable programs and avoid abrupt funding cuts that could disrupt services, even as mortality rates fluctuate. It promotes more predictable planning and sustained impact.
Case against: Critics might argue that a strict adherence to current mortality rates should be the primary driver of funding, and that mitigating 'cliffs' could mean less responsive allocation of funds to states where the crisis is most acutely worsening in real-time. It could be seen as prioritizing stability over immediate need.
Estimated impact: This affects the distribution of approximately $825 million annually (15% of $5.5 billion) among states with high opioid mortality rates.
This section creates a 'safe harbor' for high deductible health plans (HDHPs), allowing them to cover opioid overdose reversal agents without a deductible. This means that an HDHP will still be treated as an HDHP for tax purposes, even if it provides first-dollar coverage for these life-saving medications.
Section 7(b)
Why it matters:This is standard legislative practice for making technical adjustments to tax code definitions to align with new policy mandates, ensuring that individuals with HDHPs are not penalized for accessing essential health services.
Case for: Proponents argue that this safe harbor is crucial to ensure that individuals with HDHPs can access opioid overdose reversal agents without financial barriers, consistent with the broader goal of preventing overdose deaths. Without it, HDHP enrollees might delay or avoid obtaining these critical medications.
Case against: No specific opposition is typically raised against this provision, as it aligns with public health goals and removes a potential disincentive for HDHP enrollees to carry life-saving medication. Some might argue it slightly deviates from the core principle of HDHPs having a deductible for all services.
Estimated impact: This impacts all individuals enrolled in HDHPs, ensuring they can access opioid overdose reversal agents without meeting their deductible first. The fiscal impact is likely minimal as it primarily clarifies tax treatment.
This provision specifies the selection criteria for eligible states to participate in the CMI demonstration project for recovery housing. Priority is given to states that are among the top 10 for highest per capita drug poisoning deaths (2023-2025) AND among the 10 states with the lowest physician reimbursement rates for Medicaid services (2023-2025).
Section 10(h)(4)(B)(ii)
Why it matters:This is standard practice for defining eligibility criteria for targeted federal programs, ensuring that resources are directed to specific populations or regions based on data-driven metrics.
Case for: Proponents argue that targeting states with both high overdose rates and low physician reimbursement ensures that the demonstration addresses areas with the most acute need for improved access to care and where the impact of recovery housing could be most transformative. It aims to address systemic barriers.
Case against: Critics might argue that focusing on states with low physician reimbursement could exclude other high-need states where access barriers are different, or that the dual criteria are overly restrictive and might limit the generalizability of the demonstration's findings.
Estimated impact: This impacts which states will be selected for the CMI demonstration, potentially directing significant federal innovation funds and new service models to a specific subset of states.